1047644-62-1

Basic information

• Product Name: GSK-2110183C
• Synonyms: Afuresertib;GSK 2110183C;GSK2110183C;GSK-2110183C;N-((S)-1-amino-3-(3-fluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide;Afuresertib(GSK2110183C);Afuresertib, GSK-2110183, GSK-2110183B;Delitinib
• CAS NO: 1047644-62-1
• Molecular Formula: C₁₈H₁₇Cl₂FN₄OS
• Molecular Weight: 427.3231832
• EINECS: 1592732-453-0
• Product Categories: Inhibitors
• Mol File: 1047644-62-1.mol

Chemical Properties

• Boiling Point: 535.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• PKA: 13.03±0.46(Predicted)
• CAS DataBase Reference: GSK-2110183C(CAS DataBase Reference)
• NIST Chemistry Reference: GSK-2110183C(1047644-62-1)
• EPA Substance Registry System: GSK-2110183C(1047644-62-1)

Safety Data

• Hazardous Substances Data: 1047644-62-1(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
GSK-2110183C is used as an anticancer agent for the treatment of multiple myeloma. It has demonstrated synergy with bortezomib, a proteasome inhibitor, in preclinical models of the disease. By targeting the AKT pathway, GSK-2110183C can potentially enhance the efficacy of existing treatments and improve patient outcomes.
In addition to its use in multiple myeloma, GSK-2110183C may also have potential applications in other cancer types that are driven by the AKT pathway. Further research and clinical trials would be necessary to explore these possibilities and determine the full range of its therapeutic potential.

Upstream product

• 1047644-88-1 methyl 5-chloro-4-iodo-2-thiophenecarboxylate 
• 1047630-52-3 methyl 5-chloro-4-(1-methylpyrazol-5-yl)-2-thiophenecarboxylate 
• 24065-33-6 5-Chlorothiophene-2-carboxylic acid 
• 114873-01-7 N-Boc-3-fluoro-L-phenylalanine 
• 944470-56-8 tert-butyl [(1S)-1-(3-fluorobenzyl)-2-hydroxyethyl]carbamate 
• 1201923-48-9 1,1-dimethylethyl {(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}carbamate 
• 35475-03-7 methyl 5-chloro-2-thiophenecarboxylate 
• 75321-89-0 2-(3-fluorophenyl)acetaldehyde 
• 1047630-61-4 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxylic acid 
• 1047630-72-7 methyl 4-bromo-5-chlorothiophene-2-carboxylate 
• 1047645-80-6 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-2-thiophenecarboxamide 

Downstream Products

• 1047645-82-8 N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride 

Relevant articles and documents

Preparation method of Afuresertib

The invention discloses a preparation method of Afuresertib. The preparation method comprises the following steps: firstly preparing a chiral compound (alpha S)-alpha-amino-3-fluorophenyl propionitrile, and carrying out amidation reaction and nitrile group reduction reaction on the chiral compound (alpha S)-alpha-amino-3-fluorophenyl propionitrile and 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxylic acid to obtain the target product Afuresertib. The preparation method is simple in process, mild in condition, optimized in environment, improved in quality and suitable for therequirement of industrial amplification.

Preparation method of Afuresertib

The invention discloses a preparation method of Afuresertib. The Afuresertib is prepared through an amidation reaction and an ammoniation reduction reaction between (2S)-2-amino-3-(3-fluorophenyl) methyl propionate and 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxylic acid. The preparation method has the advantages of easily available raw materials, simple process, optimized environment and improved quality, and is suitable for industrial amplification requirements.

AFURESERTIB: Protein kinase B (PKB) inhibitor Oncolytic

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays key roles in cellular proliferation and survival. Mutations and alterations in this signal transduction pathway have been described in a variety of solid and hematopoietic malignancies, which may contribute to perpetuation of the disease in a number of ways. Increasing interest in targeting particular facets of this signaling cascade has led to the development of a number of novel anticancer agents, including afuresertib (GSK-2110183), an orally bioavailable pan-inhibitor of the RAC-alpha serine/threonine protein kinase, also referred to as protein kinase B or proto-oncogene c-Akt. The present review summarizes the preclinical and pharmacological aspects of afuresertib and early clinical experience.